www.fdanews.com/articles/87833-vanda-s-insomnia-agent-shows-promise-in-trial
VANDA'S INSOMNIA AGENT SHOWS PROMISE IN TRIAL
June 23, 2006
Vanda Pharmaceuticals has reported that results from a Phase II study demonstrated that its investigational agent VEC-162 improved key sleep measures in adults with transient insomnia.
The primary objectives of the study were to evaluate the efficacy of VEC-162 in shifting patients' circadian rhythm and in improving time to persistent sleep when compared with placebo.